# Diabetes Research Hub — Iteration Run Report

**Date:** 2026-06-13 (Saturday)
**Agent:** Automated research agent (scheduled task `diabetes-research-iterate`)

## Summary

Routine Saturday iteration. Corpus is in steady state — all 285 papers vetted, all 57 research paths carry a validation status. This run focused on the credibility sweep, strengthening two partially-validated paths against current external evidence, and a full pipeline rebuild. Monday-only weekly PubMed search was skipped (today is Saturday).

## Step 0–1: State load & work queue

- Loaded `agent_state.json` (last run 2026-06-12).
- Papers: 285 total — 272 VETTED, 13 FLAGGED (legitimate off-topic exclusions). No vetting backlog.
- Work queue: 21 items, mostly future-dated gap audits (next due Gap #11 ~2026-06-27, Gap #1 ~2026-06-29; rest July+). Selected the actionable items below.

## Step 4: Credibility sweep — CLEAN

- No fabricated PMIDs or "zero SAEs/zero rejection" claims in any `Analysis/Scripts/*.py`. The only `curative`/`achieves` hits are inside the verifier's own detection patterns (`verify_before_deploy.py`).
- `agent_state.json` contains PMIDs in the >=42,000,000 range. These are **not** fabrications: per `doctrine_notes`, the legacy "PMID > 42M = fabricated" ceiling is **deprecated** because real NCBI PMIDs reached the 42M range in 2026. Spot-verified four (42203900, 42160884, 42126264, 42021540) via NCBI esummary — all returned real titles/journals (Bone Marrow Transplant; J Autoimmun; J Basic Clin Physiol Pharmacol; J Biochem Mol Toxicol). Other data JSONs were CLEAN.
- FLAGGED PMID 41827829 confirmed real (present in paper_library with PMC fulltext).

## Step (P4): Path validation

**verapamil -> beta_cell — upgraded PARTIALLY_VALIDATED -> VALIDATED**
- CLVer pediatric RCT (PMID 36826844, JAMA 2023): verapamil preserved stimulated C-peptide ~30% above placebo at 52 weeks.
- Ovalle adult RCT (PMID 29988125, Nat Med 2018): positive for C-peptide AUC preservation.
- Ver-A-T1D European multicentre adult RCT (n=136, 21 sites / 6 countries; protocol/design PMID 39613428, BMJ Open 2024): underway; final peer-reviewed primary results still pending (queue item, next ~2026-07-02).
- Caveat recorded: effect is *partial* preservation; durability beyond 12 months not yet established.

**Treg_expansion -> T1D — kept PARTIALLY_VALIDATED (honest)**
- T-Rex phase 2 RCT (PMID 38718135, Sci Transl Med 2024): expanded autologous polyclonal Tregs were safe but did **not** preserve residual beta-cell function vs placebo.
- 2025 systematic review & meta-analysis (PMID 41267047, BMC Endocr Disord, 19 studies): "paradoxical dissociation" — immunotherapy/low-dose IL-2 expands Tregs and can preserve C-peptide as a biomarker without consistent HbA1c benefit.
- Conclusion: target engagement (Treg expansion) confirmed; durable clinical beta-cell preservation from Treg expansion alone remains unproven.

## Step 5: Pipeline rebuild — 41/41 [OK]

`run_quality_improvements.py` completed all 41 improvements successfully. PMID verification: 259 verified, 0 not found, 0 API errors. Only warning: abstract fetch for PMID 27512794 (a known FLAGGED off-topic paper) — benign.

## Step 6: State & git

- Recorded this run in `run_history` (now 61 runs) and reprioritized the work queue.
- **Local commit `ad7899d` created** (48 files changed). Cleared the recurring stale `.git/index.lock` / `HEAD.lock` (OneDrive fuse mount blocks `unlink`) via the mv-aside workaround.
- **`git push` BLOCKED** — no GitHub credentials in the sandbox. Branch is now **38 commits ahead of origin/main**.
  - **ACTION REQUIRED (user):** run `git push` from your machine to publish the accumulated commits.

## Next run

- Saturday -> no weekly Monday PubMed search this run.
- Upcoming due: Gap #11 audit (~2026-06-27), Gap #1 audit (~2026-06-29).
- Continue path validation on remaining partially-validated paths.

---
*Research synthesis only — not medical advice. All claims trace to cited PMIDs.*
